A b s t r a c t
According to the present World Health Organization (WHO) classification of tumors of the urinary system (2004 WHO classification), flat intraepithelial lesions of the urinary bladder are categorized as flat hyperplasia (HP), reactive atypia (RA), atypia of unknown significance (AUS), dysplasia (DP), and carcinoma in situ (CIS), as originally described. 1, 2 These terms are intended to describe a histologic spectrum of architectural and cytologic abnormalities ranging from benign atypia to unequivocal malignancy. [3] [4] [5] In the classification, DP and CIS are defined as low-and high-grade intraurothelial neoplasia, respectively. In other words, the flat urothelial lesions are subdivided into 3 subgroups: (1) nonneoplastic lesions including HP and RA, (2) AUS, and (3) neoplastic lesions, including DP and CIS. However, despite this classification scheme, in practice, the lack of reliable diagnostic criteria of flat urothelial lesions results in poor reproducibility among pathologists. In particular, the morphologic continuum between RA and AUS, AUS and DP, or DP and CIS does not provide any absolute features that allow for unequivocal distinction. Furthermore, the diagnostic terminology of AUS is considered the most controversial and least understood subtype of intraurothelial lesion.
Previous studies have demonstrated the effectiveness of immunohistochemical and fluorescence in situ hybridization (FISH) analyses for discriminating between nonneoplastic and neoplastic lesions or low-and high-grade lesions of the urinary bladder. [6] [7] [8] [9] [10] [11] [12] [13] For example, cytokeratins (CKs) such as CK14 and CK20 and markers for cell proliferation such as Ki-67, p16 INK4a , and p53 were shown to be objective markers for distinguishing CIS from nonneoplastic urothelium. Furthermore, FISH analysis has been established as a valuable Upon completion of this activity you will be able to:
• apply the World Health Organization classification of flat urothelial lesions.
• discuss the utility of immunohistochemical stains in the workup of flat urothelial lesions.
• describe the UroVysion fluorescence in situ hybridization test for urothelium and its potential use in managing patients with urothelial lesions.
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adjunct in the cytologic diagnosis of precancerous and malignant lesions of the urinary bladder. [14] [15] [16] [17] [18] [19] The purposes of this study were to determine the diagnostic variability of biopsy samples from flat intraepithelial lesions in the urinary bladder among pathologists and to make clear the usefulness of immunohistochemical and multicolor FISH analyses for solution of diagnostic variation.
Materials and Methods

Case Selection and Study of Observer Variation
Nine pathologists (A, B, C, D, E, F, G, H, and I) with experience in diagnostic urological pathology participated in the present study. The mean (range) number of years of pathology experience of the pathologists who participated in the study was 25 years (13-36 years). For the study, 23 biopsy samples of the urinary bladder from 19 patients (17 men and 2 women; mean age at diagnosis, 69.5 years) were selected from the files of Yamanashi University Hospital (Yamanashi, Japan). Case selection was done randomly by one of us (S.M.), and typical or indeterminate cases with normal to variously atypical urothelium were included in the study. The case summaries are shown in ❚Table 1❚. H&E-stained slides were reviewed independently by the members of the panel of participating pathologists. The representative histologic features of the 23 lesions are shown in ❚Image 1❚. Except for age and sex, the clinical information and results of immunohistochemical and FISH analyses were not provided to the pathologists. The members of the panel diagnosed the lesions using the following diagnostic terms: normal, HP, RA, AUS, DP, and CIS according to the WHO criteria. The term AUS may rarely be used in routine pathologic diagnosis; however, we used the term for very indeterminate cases in the study. Diagnostic agreement was concluded when more than 6 pathologists in the panel made the same diagnosis.
Immunohistochemical Analysis
Immunohistochemical analysis was performed using conventional procedures with Ventana XT System BenchMark (Ventana Japan, Tokyo, Japan). Additional 4-μm cut sections were stained with primary antibodies against CK20, high-molecular-weight (HMW) CK, Ki-67 (MIB-1), p53, or p16 INK4a . All antibodies were purchased from DAKO (Tokyo, Japan). The labeled streptavidin-biotin complex technique (I-VIEW DAB Universal Kit, Ventana Japan) was used to visualize the reaction. Abnormal expression of CK20 and HMW-CK was concluded when CK20 was expressed from the surface to middle layer or the whole layer and HMW-CK was expressed from the basal to middle layer or the whole layer of the urothelium. A negative pattern was not considered abnormal because nonneoplastic urothelium often showed no immunoreactivity to CK20 or HMW-CK owing to erosion or unknown reasons. We also evaluated 200 cells from each sample, and abnormal expression of Ki-67 and p53 was concluded to be present when numbers reached more than 5% and 10% of cells, respectively.
Multicolor FISH Study
The FISH method was performed on additional 4-μm cut sections mounted on glass slides to assess polysomy of chromosomes 3, 7, and 17 by centromeric probes and to detect deletion of p16 INK4a at the 9p21 locus using the UroVysion probe set (Vysis, Abbott, Des Plaines, IL). FISH was performed according to the recommendations of the manufacturer with minor modifications as described previously. 17, 20 The directly labeled DNA probes against the centromeric regions of chromosomes 3 (CEP3), 7 (CEP7), and 17 (CEP17) and of the 9p21 locus (LSI9p21) were labeled with SpectrumRed, SpectrumGreen, SpectrumAqua, and SpectrumGold fluorophores (Vysis), respectively. After nuclear counterstaining with 4,6-diamino-2-phenylindole dihydrochloride, the numbers of FISH signals were counted under a Zeiss microscope (Carl Zeiss Japan, Tokyo, Japan).
The numbers of FISH signals in 50 epithelial cells in the samples were recorded as 0, 1, 2, 3, or more positive chromosomes for each probe. To determine the ranges of FISH signal numbers from each probe in normal cells and to exclude the artifacts induced by the histologic sections, the frequency of polysomy of CEP3, CEP7, and CEP17 or the deletion of LSI9p21 was analyzed in 30 normal stromal cells in the samples. 
Results
Observer Variation
Representative histologic features of the 23 intraepithelial lesions of the urinary bladder from 19 cases are shown in Image 1, and the diagnoses of the lesions by the panel are shown in ❚Table 2❚. All pathologists made the same diagnosis in 2 lesions of CIS (cases 4 and 8 [9%]); however, the remaining 21 lesions had more than 2 different diagnoses. The average of κ statistics between pairs of pathologists was 0.23 (range, -0.002 to 0.51). To summarize diagnostic agreement among the 9 pathologists, we classified the 23 lesions into 3 groups and 5 subgroups. Group 1 included benign (subgroup A) and malignant (subgroup B) lesions with the same diagnosis from at least 6 pathologists. Group 2 included benign (subgroup A) and malignant (subgroup B) lesions with diagnostic agreement of nonneoplasia (normal, HP, or RA) or neoplasia (DP or CIS) from at least 6 pathologists. Group 3 included lesions without diagnostic agreement. Classification of the 23 intraepithelial lesions into the 3 groups is shown in ❚Table 3❚. The numbers of cases in groups 1, 2, and 3 were 8 (35%), 8 (35%), and 7 (30%), respectively.
Diagnostic variation for each pathologist is summarized in ❚Table 4❚. Preference for the diagnostic terms normal and AUS varied among pathologists. The diagnostic incidence of normal for the 23 lesions was 0 (0%; pathologist F) to 8 (35%; pathologist I) (mean ± SD, 16.9% ± 11.4%). The diagnostic DP  DP  DP  CIS  RA  AUS  NM  DP  2  HP  HP  HP  NM  RA  DP  DP  AUS  CIS  3  AUS  NM  NM  NM  DP  RA  NM  RA  NM  4  CIS  CIS  CIS  CIS  CIS  CIS  CIS  CIS  CIS  5  AUS  AUS  AUS  NM  DP  DP  RA  RA  NM  6  DP  CIS  CIS  CIS  CIS  CIS  AUS  DP  CIS  7  RA  AUS  NM  RA  DP  DP  DP  DP  AUS  8  CIS  CIS  CIS  CIS  CIS  CIS  CIS  CIS  CIS  9  RA  AUS  HP  AUS  NM  DP  NM  NM  AUS  10  CIS  AUS  NM  AUS  CIS  DP  RA  DP  AUS  11  DP  DP  CIS  CIS  CIS  CIS  DP  DP  CIS  12  AUS  DP  DP  NM  CIS  RA  DP  DP  DP  13  CIS  CIS  AUS  CIS  CIS  CIS  CIS  DP  CIS  14  RA  AUS  NM  RA  DP  RA  NM  AUS  NM  15  DP  AUS  NM  RA  DP  RA  RA  AUS  NM  16  RA  NM  DP  NM  CIS  RA  NM  NM  NM  17  DP  DP  DP  NM  CIS  RA  RA  DP  NM  18  RA  RA  RA  RA  RA  DP  RA  RA  AUS  19 Lesion incidence of AUS for the 23 lesions was 0 (0%; pathologists E and F) to 6 (26%; pathologist B) (mean ± SD, 12.6% ± 8.3%).
Agreement by at least 6 pathologists regarding the distinction between nonneoplastic and neoplastic lesions was achieved in 16 (70%) of 23 lesions. The preference ratio of neoplasia to nonneoplasia (0.9 for pathologist G to 4.8 for pathologist E) and CIS to DP (0.2 for pathologist H to 4.0 for pathologist D) also varied among pathologists.
Immunohistochemical Study
The 23 lesions stained in the present study showed varied expression of CK20 that included a normal pattern, which was positive only in surface cells or negative owing to erosion ❚Image 2A❚; an abnormal pattern, represented by positive staining in the surface to middle or whole layer; and a negative pattern ❚Image 2B❚ and ❚Image 2C❚. Expression of HMW-CK also varied among the lesions and included a normal pattern, which was positive in the basal layer of the urothelium ❚Image 2D❚; an abnormal pattern, represented by positive stain in the basal to middle or whole layer; and a negative pattern ❚Image 2E❚ and ❚Image 2F❚. Abnormal expression of CK20 was found in 9 (39%) of all lesions, 1 (20%) of 5 in groups 1A and 2A, and 5 (83%) of 6 in group 1B. Abnormal expression of HMW-CK was found in 12 (52%) of all lesions, 1 (20%) of 5 in groups 1A and 2A, and 9 (82%) of 11 in groups 1B and 2B. Expression of CK20 and HMW-CK is summarized in ❚Table 5❚.
Cells positive for Ki-67 were found in 16 lesions (70%) ❚Image 2G❚ ( Table 5 ). The MIB-1 index (percentage of Ki-67 positive cells) in all lesions was 0% to 45%, with 8 lesions showing an MIB-1 index of greater than 5%. In group 1B, all lesions tested showed an MIB-1 index of greater than 5%. p53+ cells were found in all lesions (Image 2G and Table 5 ). The p53 index (percentage of p53+ cells) in all lesions was 1% to 24%, with 9 lesions showing a p53 index of greater than 10%. A p53 index of greater than 10% was shown in 4 (80%) of 5 lesions in group 1B and 3 (60%) of 5 lesions in group 2B. p16 INK4a + cells were found in 5 lesions. Except for 1 lesion (case 14), p16 INK4a + cells were found only in groups 1B and 2B.
Multicolor FISH Study
The representative cases with or without polysomy of the centromeric regions for CEP3, CEP7, and CEP17 and of the 9p21 locus are shown in ❚Image 3❚. As a control, the frequency of normal stromal cells with more than 3 FISH signals of each centromeric probe for CEP3, CEP7, and CEP17 in all samples were 1.5% ± 2.1%, 0.3% ± 1.0%, and 0.3% ± 1.0%, respectively. The frequency of normal stromal cells with no FISH signal for LSI9p21 among all samples was 12.5% ± 6.7%. To detect polysomy of CEP3, CEP7, and CEP17 and the relative deletion of 9p21, a 4-fold SD was applied as a cutoff level, and a threshold frequency of epithelial cells with more than 3 FISH signals was defined as 9.9% for CEP3, 4.3% for CEP7, and 4.3% for CEP17, while a threshold frequency of epithelial cells with no FISH signal for LSI9p21 was defined as 39.4%. A lesion was considered aberrant if the lesion indicated more than 2 of CEP3, CEP7, or CEP17 as polysomy or there was an LSI9p21-indicated deletion. Based on the aforementioned criteria, 8 lesions showed polysomy of CEP3, CEP7, or CEP17 or deletion of LSI9p21. Of all lesions, 8 were categorized as aberrant, as were 4 of 5 lesions in group 1B and 3 of 5 in group 2B.
Discussion
The 2004 WHO classification categorized flat intraepithelial lesions of the urinary bladder into normal urothelium, HP, RA, AUS, DP, and CIS. 2 Biopsy remains the "gold standard" for the diagnosis of flat intraepithelial lesions. Clinical therapy for the intraepithelial disease is based on biopsy diagnosis and includes bacille Calmette-Guérin and/or chemotherapy for CIS, careful follow-up examination for DP, and no therapy for nonneoplastic lesions. 18 Diagnostic approaches to flat intraepithelial lesions defined by the WHO classification have been proposed based on cytologic and histologic findings; however, high observer variation for diagnosis has been suggested. Clinically, observer variation in flat intraurothelial lesions is problematic. 4 However, the usefulness of molecular rate for diagnosis was statistically very low. The interobserver agreement by more than 6 pathologists was 35% for each subtype (group 1) and 70% for nonneoplastic or neoplastic lesions (group 2). However, 30% of cases (group 3) had no diagnostic agreement among pathologists and were given various diagnoses from nonneoplasia to neoplasia. The issues for diagnostic reproducibility of the intraurothelial lesion were classified into 4 major points: (1) range of normal urothelium, and immunohistochemical analyses and the reproducibility of the histologic diagnosis of the flat intraepithelial lesions have not been evaluated. This study analyzed 23 selected samples with normal to variously atypical lesions and critical interobserver variation, even though the sample was small. Only 2 CIS cases (9%) had the same diagnosis by all pathologists. No pair of pathologists showed a κ statistic of more than 0.6, and the concordance Previous studies have demonstrated the usefulness of various immunohistochemical and genetic analyses as indicators of neoplastic change in urothelial mucosa. 11, 17, 21 In the present study, we applied 6 types of analyses, including an immunohistochemical study involving CK20, HMW-CK, Ki-67, p53, and p16 INK4a and a FISH study to detect polysomy of chromosomes 3, 7, and 17 or deletion of 9p21. In the normal urothelium, CK20 is expressed only in umbrella cells, while HMW-CK is expressed only in the basal cell layer. 7, 8 Previous studies have shown that the incidence of CK20 is low in RA (4%) and AUS (30%) and high in CIS (>70%), 7, 9 while HMW-CK expression was found in more than 60% of urothelial malignancies. 22 In the present study, except for case 1, all other neoplastic lesions with diagnostic agreement (groups 1B and 2B) showed aberrant expression of CK20 and HMW-CK.
(2) difference between nonneoplastic and neoplastic lesions, (3) controversial term of AUS, and (4) difference between DP and CIS. A variety of diagnostic preferences for normal (0%-35%) and AUS (0%-26%) was found, along with a variety of preference ratios for neoplasia (DP or CIS) to nonneoplasia (normal, HP, or RA) (0.9 to 4.8) or CIS to DP (0.2 to 4.0) among pathologists. This poor diagnostic agreement in all 4 major classifications is due to the lack of reliable diagnostic criteria for flat intraepithelial lesions, which have a morphologic continuum and no absolute features for unequivocal distinction such as those for squamous intraepithelial lesions of the uterine cervix. Surprisingly, there was a range of normal urothelium and differing terminology for AUS among pathologists. Moreover, poor diagnostic agreement and difficulty in discrimination between DP and CIS are problematic for clinical therapy. B/PBL, basal/parabasal layer; CK20, cytokeratin 20; FISH, fluorescence in situ hybridization; HMW-CK, high-molecular-weight cytokeratin; ML, middle layer; ND, not done; S, surface; WL, whole layer; +, positive; -, negative. * Group 1 included benign (subgroup A) and malignant (subgroup B) lesions with the same diagnosis from at least 6 pathologists. Group 2 included benign (subgroup A) and malignant (subgroup B) lesions with diagnostic agreement of nonneoplasia (normal urothelium, hyperplasia, or reactive atypia) or neoplasia (dysplasia or carcinoma in situ) from at least 6 pathologists. Group 3 included lesions without diagnostic agreement. FISH data are represented by incidence (percentage) of cells with more than 3 FISH signals of each centromeric probe for chromosomes 3 (CEP3), 7 (CEP7), and 17 (CEP17), or incidence (percentage) of cells with no FISH signal of LSI9p21. Based on data for stromal cells, the threshold incidence of aberrant epithelial cells with more than 3 FISH signals was defined as 9.9% for CEP3, 4.3% for CEP7, and 4.3% for CEP17, and the threshold incidence of aberrant epithelial cells with no FISH signal for the 9p21 locus (LSI9p21) was defined as 39.4%. In FISH analysis, a lesion was considered aberrant if the lesion indicated more than 2 signals for CEP3, CEP7, or CEP17 or indicated polysomy or LSI9p21 deletion. † Aberrant incidence. ‡ Aberrant pattern or value. agreement (groups 1B and 2B), whereas almost no immunoreactivity was detected in nonneoplastic lesions with diagnostic agreement (groups 1A and 2A).
Previous studies demonstrated that genetic analysis of urothelial lesions by FISH using the UroVysion probe set could successfully detect malignancy in cytologic samples. 14, 17, 25 Furthermore, FISH analysis was even shown to be effective for the differential diagnosis of flat urothelial lesions in biopsy cut sections. 16 Taking into account the artifacts induced by the histologic sections, we considered the sample abnormal if the lesion indicated more than 2 of CEP3, CEP7, or CEP17 as polysomy or deletion of 9p21. Based on these FISH analysis criteria, genetic aberration was found in 70% of neoplastic lesions with diagnostic agreement (groups 1B and 2B), while only 1 case (case 18) among 5 nonneoplastic lesions with diagnostic agreement (groups 1A and 2A) demonstrated genetic aberration.
Overall, when taking together the histopathologic diagnosis and immunohistochemical and FISH analyses, Abnormal expression of CK20 and HMW-CK was found only in neoplastic lesions, whereas abnormal expression of either CK20 or HMW-CK was also detected in 2 nonneoplastic lesions with diagnostic agreement (groups 1A). Ki-67, a marker of cell proliferation, and p53 and p16 INK4a , which are tumor suppressor proteins, are abnormally expressed in urothelial malignancy, although indexes of Ki-67 and p53 for CIS vary in previous reports. Based on the study by Cina et al 23 and to detect both DP and CIS, we defined expression of Ki-67 and p53 as abnormal when the Ki-67 and p53 indexes were more than 5% and 10%, respectively. The neoplastic group with diagnostic agreement (groups 1B and 2B) showed high Ki-67 and p53 indexes in 70% of lesions, while except for case 18, all other nonneoplastic lesions with diagnostic agreement (groups 1A and 2A) showed a low Ki-67 index.
Immunoreactivity for p16 INK4a is one of most useful markers for distinguishing a carcinoma from severe reactive atypia in situ. 13, 24 In the present study, p16 INK4a immunoreactivity was found in 36% of neoplastic lesions with diagnostic 3 We demonstrated problematic interobserver and intraobserver diagnostic variation for flat intraepithelial lesions from urinary bladder biopsy tissue. Lesions with more than 2 aberrant results on immunohistochemical and genetic analyses indicated a more likely neoplastic change. However, these ancillary analyses failed to discriminate between DP and CIS and to reliably divide the flat intraepithelial lesions without diagnostic agreement to the appropriate classification. Logical diagnostic algorithms and ancillary analyses based on the carcinogenic genetic event will be required to improve interobserver and intraobserver diagnostic variation in flat intraepithelial lesions of the urinary bladder.
